Premium
Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging
Author(s) -
Johnson Keith A.,
Sperling Reisa A.,
Gidicsin Christopher M.,
Carmasin Jeremy S.,
Maye Jacqueline E.,
Coleman Ralph E.,
Reiman Eric M.,
Sabbagh Marwan N.,
Sadowsky Carl H.,
Fleisher Adam S.,
Murali Doraiswamy P.,
Carpenter Alan P.,
Clark Christopher M.,
Joshi Abhinay D.,
Lu Ming,
Grundman Michel,
Mintun Mark A.,
Pontecorvo Michel J.,
Skovronsky Daniel M.
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.10.007
Subject(s) - dementia , medicine , amyloid (mycology) , positron emission tomography , cognitive impairment , alzheimer's disease , apolipoprotein e , disease , pittsburgh compound b , β amyloid , standardized uptake value , pathology , nuclear medicine
Objective To evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs). Methods Florbetapir PET was acquired in 184 subjects (45 AD patients, 60 MCI patients, and 79 HCs) within a multicenter phase 2 study. Amyloid burden was assessed visually and quantitatively, and was classified as positive or negative. Results Florbetapir PET was rated visually amyloid positive in 76% of AD patients, 38% of MCI patients, and 14% of HCs. Eighty‐four percent of AD patients, 45% of MCI patients, and 23% of HCs were classified as amyloid positive using a quantitative threshold. Amyloid positivity and mean cortical amyloid burden were associated with age and apolipoprotein E ε4 carrier status. Conclusions The data are consistent with expected rates of amyloid positivity among individuals with clinical diagnoses of AD and MCI, and indicate the potential value of florbetapir F18 PET as an adjunct to clinical diagnosis.